Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01896778 | Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer | completed | N/A | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT01462890 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer(BOOST) | completed | Phase 3 | 927 | AGO Study GroupOTHER | 6 | Jul 20, 2022 | clinicaltrials |
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | completed | Phase 2 | 69 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | completed | Phase 1 | 15 | Clemens TempferOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05448586 | Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? | completed | — | 132 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | completed | Phase 1 | 98 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03509636 | A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer | completed | Phase 1 | 113 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 3 | 361 | Hoffmann-La RocheINDUSTRY | 14 | Jun 21, 2022 | clinicaltrials |
| NCT02317705 | Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer | completed | Phase 2 | 48 | On Target Laboratories, LLCINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04630327 | Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory | completed | — | 226 | Kazakh Medical University of Continuing EducationOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02736305 | Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 21 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT01591772 | Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer | completed | — | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03505307 | Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) | completed | — | 846 | AstraZenecaINDUSTRY | 0 | Jun 1, 2022 | clinicaltrials |
| NCT04360629 | Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer | completed | N/A | 151 | Jun ZhangOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT02593422 | Writing About Experiences With Ovarian Cancer | completed | N/A | 73 | University of Maryland, College ParkOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT00432094 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | completed | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT02952521 | Ovarian Tumor Biopsies to Study Response to Treatments | completed | — | 5 | University Health Network, TorontoOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02681237 | A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | completed | N/A | 34 | University Health Network, TorontoOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03372720 | Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors | completed | N/A | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03028519 | Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | completed | Early Phase 1 | 81 | University of OklahomaOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | completed | Phase 2 | 46 | Massachusetts General HospitalOTHER | 0 | Apr 14, 2022 | clinicaltrials |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | completed | Phase 2 | 272 | AstraZenecaINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02324439 | Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission | completed | Phase 1 | 15 | Southern Illinois UniversityOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03881683 | Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer(BOVARY Pilot) | completed | N/A | 24 | Institut de Cancérologie de LorraineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04651920 | A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer | completed | — | 240 | Lei LiOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | completed | Phase 2 | 376 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02608684 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer(PemCiGem) | completed | Phase 2 | 21 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT00740116 | Tranexamic Acid in Surgery of Advanced Ovarian Cancer | completed | Phase 4 | 100 | Preben Kjolhede, MD, professorOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03378128 | Debulking Surgery in Ovarian Cancer(MIID-SOC) | completed | N/A | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02916875 | Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making | completed | — | 223 | Vejle HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04154163 | Appropriate Dosing to Optimise Personalised Cancer Treatments(ADOPT) | completed | — | 18 | University of DundeeOTHER | 1 | Feb 28, 2022 | clinicaltrials |
| NCT02316834 | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(POSITION) | completed | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02855697 | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer(MOLTO) | completed | Early Phase 1 | 28 | The Christie NHS Foundation TrustOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT05246462 | The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients | completed | N/A | 68 | Akdeniz UniversityOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02824328 | A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | completed | — | 47 | Duke UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT01379989 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer(INOVATYON) | completed | Phase 3 | 617 | Mario Negri Institute for Pharmacological ResearchOTHER | 11 | Feb 9, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT03180307 | OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer | completed | Phase 3 | 140 | On Target Laboratories, LLCINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT01167842 | Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer) | completed | — | 31 | University of WashingtonOTHER | 1 | Feb 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 26, 2022source: clinicaltrials